-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點總結如下：鑑於第一季財報發布後我們下調了對SNA的12個月目標價，我們將目標價從330美元下調至325美元。我們更新後的目標價相當於2027年每股收益預期21.12美元的15.5倍（此前預期為21.28美元；2026年每股收益預期從19.91美元下調至19.63美元），與SNA的長期歷史平均市盈率相符，但低於工業機械行業的同行。在SNA發布第一季財報後，我們維持「強烈賣出」評等不變。儘管我們認為，如果基本獲利能力沒有改善，SNA第一季的利潤率收縮不會構成生存威脅，但其獲利成長將受到很大限制。關稅和原材料成本上漲在第一季侵蝕了SNA的利潤，但有機銷售成長更為積極。 OEM 經銷商的需求逆風導致我們下調了 2026 年和 2027 年的每股盈餘成長預期，我們認為，維修系統對有機銷售擴張的貢獻將會減少。
Related Articles
Research
Research Alert: CFRA Keeps Buy Opinion On Shares Of Invesco Ltd.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target price by $2 to $29, valuing IVZ shares at 9.5x our 2027 adjusted EPS estimate of $3.05 and at 10.9x our 2026 EPS estimate of $2.65 (lowered today by $0.05), versus the one-year average forward multiple of 10x and a bifurcated peer average of 16x. Invesco delivered Q1 2026 adjusted EPS of $0.57, missing our $0.62 estimate but near the $0.58 consensus, while posting its 11th consecutive quarter of positive organic growth with $21.8B in net long-term inflows. Investment management fees surged 25.6% Y/Y to $1.38B due to the QQQ conversion benefits and higher average AUM, though service fees declined 18.6% due to QQQ's structural changes. We view the QQQ conversion as materializing as expected, contributing meaningfully to revenue growth while demonstrating IVZ's ability to capture more fee revenue from its flagship product. Currently trading at 9.7x our 2026 EPS estimate and yielding 3.3%, we view the shares as undervalued.
$IVZ
Oil & Energy
US Oil Update: Futures Slide on Hopes for US-Iran Talks, Hormuz Reopening
Crude oil futures retreated in after-hours trading on Friday after reports that Iran had sent a new peace proposal to the US via Pakistani mediators, easing fears of a further supply disruption from the Middle East and raising hopes for the reopening of the Strait of Hormuz.Front-month West Texas Intermediate crude futures slipped by 2.45% to $102.50 per barrel, while Brent futures were down by 1.21% to $109.06/bbl.On Friday, President Trump sent letters to Congress explaining that, due to the ceasefire, he doesn't need its authorization for military operations in Iran, even though the conflict hit the 60-day mark this week."On April 7, 2026, I ordered a 2-week ceasefire. The ceasefire has since been extended. There has been no exchange of fire between United States Forces and Iran since April 7, 2026. The hostilities that began on February 28, 2026, have terminated," Trump said in letters to the House and the Senate.Trump said that despite the success of US operations against Iran and continued efforts to secure peace, the threat posed by Tehran to the US and its forces remains significant.The IRGC Navy command said it will enforce "new rules" over waters near Iran's coast in the Arabian Sea and the Hormuz, making it "a source of security and prosperity for the region."Iran reportedly sent its latest proposal for negotiations with the US to Pakistani mediators on Thursday, according to media reports, as Trump threatens to maintain the blockade of Iranian ports amid behind-the-scenes diplomacy to end the Middle East conflict.The US reportedly sent its list of amendments on Monday to reinsert the nuclear issue into the agreement under discussion, with one of the amendments demanding that Iran commit to not attempting to move any enriched uranium.On Friday, the US Department of the Treasury's Office of Foreign Assets Control said it could sanction vessels that pay tolls to Iran for safe transit through the Strait of Hormuz, even if those payments are made in the form of charitable donations to Iranian NGOs.The Department said Iranian demands for toll payments may include fiat currency, digital assets, offsets, informal swaps, or charitable donations made to the Iranian Red Crescent Society, Bonyad Mostazafan, or Iranian embassy accounts.Traffic through the Hormuz was cut by half on April 30 to seven crossings from the previous day, with traffic split between four commercial and three non-commercial movements, according to Kpler.
Research
Research Alert: CFRA Maintains Buy Rating On Shares Of Illumina
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month price target to $161 from $140, 31x our 2026 EPS estimate (up to $5.18 from $5.13; 2027 estimate up to $5.89 from $5.81), a premium to ILMN's one-year historical forward average of 24x. We were encouraged by ex-China organic sales rising ~3.5% Y/Y in Q1, while adjusted operating margin rose 150 bps Y/Y to 21.9%. We look positively on recent Congressional action to modestly increase the National Institutes of Health (NIH) budget (~1%) rather than the dramatic cuts initially feared by investors, though ILMN's guidance implies continued pressure in academic end markets in 2026. Excluding China, sequencing consumables within research and applied was down 12% Y/Y in Q1, though clinical consumables sales rose 20% Y/Y. Positively, ILMN placed over 80 NovaSeq X instruments (up 20 Y/Y) during the quarter, indicating strong momentum.
$ILMN